9 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Central Nervous System Diseases"
Show Display Options
Rank Status Study
1 Recruiting Telephone-Based Counseling for Depression in Parkinson's Disease
Conditions: Depression;   Parkinson's Disease
Interventions: Behavioral: TH-CBT;   Other: Enhanced Usual Care
2 Recruiting Telehealth Cognitive Behavioral Therapy for Depression in Parkinson's Disease (PD)
Conditions: Depression;   Parkinson's Disease
Interventions: Behavioral: TH-CBT;   Other: Standard Care
3 Recruiting Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
Condition: Brain Metastases
Intervention: Drug: RRx-001 + WBRT
4 Recruiting Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Conditions: Acute Lymphoblastic Leukemia;   Brain Neoplasm;   Hodgkin Lymphoma;   Rhabdomyosarcoma
Interventions: Procedure: Assessment of Therapy Complications;   Other: Questionnaire Administration
5 Recruiting Post Market Surveillance Study of the Wingspan Stent System
Condition: Intracranial Atherosclerosis
Intervention: Device: Wingspan Stent System
6 Recruiting International Guillain-Barré Syndrome Outcome Study
Conditions: Guillain-Barré Syndrome;   Miller Fisher Syndrome
Intervention:
7 Recruiting Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III
Condition: Intracerebral Hemorrhage
Intervention: Drug: rt-PA
8 Recruiting Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
Conditions: Cushing's Disease;   Acromegaly
Interventions: Drug: Pasireotide s.c.;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin;   Drug: Pasireotide LAR;   Drug: Metformin
9 Recruiting Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Condition: Acromegaly
Interventions: Drug: Octreotide capsules;   Drug: Injectable Somatostatin Analogs (octreotide or lanreotide);   Drug: Cabergoline

Study has passed its completion date and status has not been verified in more than two years.